# SS-20 Peptide: Evidence, Mechanism & Legal Status

> A clinical monograph on SS-20 — the Szeto-Schiller mitochondria-targeting tetrapeptide that protects mitochondria without antioxidant chemistry. Deep preclinical data, no human trials, and unapproved research-only status in 2026.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
SS-20 is a Szeto-Schiller mitochondria-targeting tetrapeptide that protected neurons and heart tissue in animal models **without scavenging free radicals** — the central evidence that the SS peptide class works by binding cardiolipin and stabilizing the inner mitochondrial membrane, not by antioxidant chemistry. Its highest evidence grade is **C (preclinical only)**: there are **no SS-20 human trials of any phase**, no approved dose, and no FDA approval. The clinical torch was carried by its sibling SS-31/elamipretide.[1](https://peptidevox.com/#r1)[6](https://peptidevox.com/#r6)

SS-20 (sequence Phe-D-Arg-Phe-Lys-NH2) is a synthetic, cell-permeable, mitochondria-targeting tetrapeptide from the Szeto-Schiller ("SS") series. It is closely related to but distinct in sequence from SS-31/elamipretide, and its scientific importance is almost entirely mechanistic rather than therapeutic.[1](https://peptidevox.com/#r1) This monograph separates what is genuinely demonstrated in animals from what is merely extrapolated to humans.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. SS-20 has no approved human indication and no human trials; it is an investigational research compound sold, when sold, as "not for human use." Dosing figures are reported strictly as seen in the preclinical literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is SS-20 and how does it work?

SS-20 is a four-residue aromatic-cationic peptide, Phe-D-Arg-Phe-Lys-NH2, carrying a net +3 charge at physiological pH. The D-arginine and C-terminal amidation confer resistance to peptidase degradation, and the alternating aromatic and basic motif is the structural signature of the Szeto-Schiller family.[1](https://peptidevox.com/#r1) The defining contrast with its sibling SS-31 (D-Arg-2',6'-dimethyl-Tyr-Lys-Phe-NH2) is that SS-20 substitutes a plain phenylalanine for SS-31's dimethyltyrosine — the residue responsible for SS-31's free-radical-scavenging activity — so SS-20 has minimal intrinsic antioxidant capacity.[1](https://peptidevox.com/#r1)

Despite their strong cationic charge, SS peptides cross the plasma membrane in an energy-independent, non-saturable manner and concentrate roughly 1,000-5,000-fold in the inner mitochondrial membrane, which is uniquely enriched in the anionic phospholipid cardiolipin.[2](https://peptidevox.com/#r2) The peptide associates with cardiolipin-rich bilayers and modulates membrane surface electrostatics, which is proposed to stabilize cristae architecture, support electron-transport-chain organization, and preserve oxidative phosphorylation.[2](https://peptidevox.com/#r2)

The pivotal mechanistic observation comes from SS-20 itself: because it lacks scavenging side chains yet is still protective, the SS peptides' efficacy cannot be explained by antioxidant chemistry alone. Antioxidant scavenging would be stoichiometric — consumed roughly one-to-one with radicals — whereas the protection observed is more consistent with a catalytic, structural effect on the membrane.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2) The currently favored mechanism is: cardiolipin binding leads to cristae and inner-membrane stabilization, which preserves ATP synthesis and inhibits opening of the mitochondrial permeability transition pore (mPTP), reducing apoptosis and secondary reactive-oxygen-species generation.[1](https://peptidevox.com/#r1) From a functional, root-cause framing, SS-20 is notable precisely because it addresses mitochondrial structural integrity rather than mopping up downstream free radicals. SS-20-specific human pharmacokinetics are not available; in published work it is given parenterally, consistent with negligible oral bioavailability for a charged tetrapeptide.[3](https://peptidevox.com/#r3)

## What is the evidence by indication?

No human efficacy trials — randomized, cohort, or open-label — exist for SS-20 in any indication. Every claim below is animal or in-vitro, graded C. A useful complement is the U.S. National Library of Medicine's trial registry at [ClinicalTrials.gov](https://clinicaltrials.gov/), which lists registered human studies for the sibling SS-31/elamipretide but none for SS-20 itself — a concrete marker of how early SS-20's evidence base remains.

  SS-20 evidence by indication

    IndicationBest evidenceGrade

    Neuroprotection — Parkinson's (MPTP model)Mouse MPTP model: ~40% attenuation of striatal dopamine depletion, full protection of nigral TH+ neuronsC (preclinical)
    Cardiac / heart-failure protectionMouse Ang-II / Gaq stress models; analog SBT-20 reduced rat infarct size in ischemia-reperfusionC (preclinical)
    Renal protectionAnalog SBT-20 reduced inflammation and oxidative stress in chronic-renal-failure modelC (analog data)
    Other neurodegeneration (Alzheimer's, ischemia)Mechanistically relevant, but published efficacy data are for SS-31, not SS-20C-to-D (extrapolation)

The neuroprotection data are the most direct for SS-20 itself. In C57BL/6 mice given MPTP (10 mg/kg, three doses), SS-20 at 4 mg/kg intraperitoneally — dosed 30 minutes before each MPTP dose, then 1 and 12 hours after the last — attenuated roughly 40% of MPTP-induced striatal dopamine depletion (p Proven vs hyped
Proven in humans: nothing. SS-20 has no human trials of any phase, no approved dose, and no FDA approval. Hyped: any consumer claim of human mitochondrial, anti-aging, or athletic benefit, which extrapolates rodent findings. What SS-20 genuinely established is mechanistic — that the SS peptide class protects mitochondria by stabilizing membranes, not by antioxidant action.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2)

## What doses appear in the literature, and how safe is SS-20?

Doses are reported strictly as information, not a protocol — there is no validated human dose, no clinical protocol, and no approved product. In the mouse MPTP neuroprotection work, SS-20 was given at 4 mg/kg intraperitoneally, timed around the neurotoxin challenge.[1](https://peptidevox.com/#r1) For the cardiac analog SBT-20 in rat ischemia-reperfusion, 0.3-3 mg/kg/h was infused intravenously, with 1 micromolar used in isolated-heart perfusate.[3](https://peptidevox.com/#r3) Administration is parenteral only in studies; as a charged tetrapeptide, oral bioavailability is expected to be negligible, and no standardized reconstitution or storage specifications exist in peer-reviewed human literature because no human formulation exists.[5](https://peptidevox.com/#r5)

On safety, SS-20 human data simply do not exist — no phase 1 tolerability, no adverse-event registry, no human pharmacokinetics or toxicology. The only relatable context is class read-across to SS-31/elamipretide, which is generally well tolerated in humans, with the most common adverse events being injection-site reactions (pain, redness, swelling) plus occasional headache, dizziness, nausea, abdominal pain, and fatigue, and rare hypersensitivity or urticaria; no significant changes in vitals, labs, or ECG appeared across long open-label extension.[5](https://peptidevox.com/#r5)[6](https://peptidevox.com/#r6) These are not verified for SS-20. Unlike pro-angiogenic peptides, mitochondrial-targeting peptides show no clear tumor-promotion signal in the literature, but SS-20's long-term and oncologic safety remain entirely uncharacterized, and any unapproved research peptide carries risks of contamination, mis-identification, and dosing error.[12](https://peptidevox.com/#r12) Pregnancy and lactation: no data, avoid.

## What is the FDA and WADA status in 2026?

SS-20 is not FDA-approved, is not an approved drug or recognized dietary ingredient, and does not appear as a sanctioned 503A or 503B compounding bulk substance. When sold, it is offered only as a research chemical labeled "not for human use" — a category the FDA has repeatedly challenged when vendors signal human use.[11](https://peptidevox.com/#r11)[12](https://peptidevox.com/#r12) The critical cross-reference is the sibling peptide: on September 19, 2025 the FDA granted accelerated approval to elamipretide HCl (FORZINITY, SS-31) — the first FDA-approved mitochondria-targeted therapeutic — for muscle strength in Barth syndrome (≥30 kg), based on knee-extensor strength as an intermediate endpoint.[6](https://peptidevox.com/#r6)[7](https://peptidevox.com/#r7) That approval applies to SS-31, not SS-20; SS-20 has no comparable regulatory standing.

For athletes, SS-20 is not named on the WADA Prohibited List, but as a non-approved pharmacological substance it is captured under the catch-all S0 (non-approved substances) clause — the same principle WADA and USADA apply to other experimental research peptides.[10](https://peptidevox.com/#r10) Any WADA-tested athlete should treat SS-20 as off-limits.

**Bottom line.** SS-20 is a mechanistically important but clinically unproven Szeto-Schiller peptide — the "negative control that worked." By protecting mitochondria in Parkinson's and cardiac-injury models without any ROS-scavenging chemistry, it demonstrated that the SS peptides act chiefly by binding cardiolipin and stabilizing the inner mitochondrial membrane and mPTP, a finding that reshaped the entire class's mechanism.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2) What is proven is preclinical mitochondrial protection (Grade C); what is unproven is any human benefit. Treat SS-20 as an experimental laboratory tool, not a therapy. Regulatory facts here are current as of June 2026 and should be re-verified for later developments.

---
Source: https://peptidevox.com/peptide-encyclopedia/glutathione-disulfide
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt